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Backgrounds/Aims: This study evaluated the hemostatic effects of a novel oxidized regenerated cellulose, SurgiGuard®, 
during liver surgery, using a reproducible and clinically relevant animal model. Methods: Fifteen mini-pigs underwent 
left partial hepatectomy. They were randomized to treatment of the resected surface with SurgiGuard® (Group C [test], 
n=5), Surgicel® (Group B [reference], n=5), or nothing (Group A [control], n=5). Blood loss was measured 5, 7 and 
9 min after resection. Time to hemostasis was recorded. Mini-pigs were necropsied 4 or 6 weeks postoperatively to 
evaluate toxicity changes and material dissolution. Results: The median resected liver weight was 2.13 g (2.02-2.20) 
in control group, 2.04 g (2.01-2.13) in reference group, and 2.01 g (1.99-2.12) in test group (p=0.024). Median total 
blood loss was 57.18 g (52.02-59.54) in control group, 32.52 g (27.66-35.10) in reference group, and 35.52 g 
(25.70-38.71) in test group (p=0.008). Blood loss at 0-5 minutes and 7-9 minutes was significantly different between 
groups (p=0.009 and p=0.006, respectively). At necropsy, no hematomas, granulomas, or adhesions were noted in 
any group. Histopathological analysis revealed no changes suggesting toxicity related to SurgiGuard®. Conclusions: 
SurgiGuard® is as effective as Surgicel® in achieving hemostasis after porcine partial liver resection. (Korean J 
Hepatobiliary Pancreat Surg 2016;20:102-109)
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INTRODUCTION
Postoperative morbidity and mortality after hep-
atectomy are adversely affected by blood loss and blood 
transfusion.1 There are several hemostatic methods to con-
trol bleeding. Mechanical techniques include manual pres-
sure and ligation. Although these techniques are the oldest 
and most flexible method, they can be labor-intensive and 
add time to the operation.2 Thermal methods, such as 
electrocauterization, laser cauterization, or argon beam, 
can also be useful methods. However, these methods cre-
ate necrotic tissue, which increases the rate of infection 
and may lead to impaired healing. Furthermore, these con-
ventional techniques and methods are sometimes difficult 
to apply because of difficulty in accessing the areas of 
bleeding.3 Topical hemostatic agents may be useful in 
such situations. Currently, several hemostatic agents are 
commercially available. Broadly, these agents are one of 
two types: passive or active. Active agents, such as throm-
bin, fibrin sealants, and hemostatic patches, provide bio-
logically active components of the coagulation cascade. In 
contrast, passive agents, such as oxidized regenerated cel-
lulose, gelatin sponges, and collagen pads and sponges, 
cause the activation of the coagulation cascade.4
Among the passive hemostatic agents, oxidized regen-
erated cellulose (ORC) has been in use for several 
decades. ORC contributes to hemostatic action by absorp-
tion of blood, surface interaction with platelets and pro-
teins, and coagulation cascade activation.5 Since ORC was 
first reported in 1943, several commercial products have 
been used.6 Surgicel® was approved by the United States 
Food and Drug Administration (FDA; http://www.fda.gov/) 
in 1960 for control of capillary, venous, and small arterial 
hemorrhage when standard surgical techniques are in-
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Fig. 1. SurgiGuard-fabric® is a woven patch type of oxidized
regenerated cellulose.
effective or impractical. ORCs are frequently used in hep-
atopancreatobiliary surgery, especially liver resections.7
A novel ORC system, SurgiGuard® (Samyang 
Biopharmaceuticals Corp.), has received approval from 
the Korean FDA (product license no. 47, 30/09/2014 
KFDA). The present study was performed to evaluate the 
hemostatic effects of SurgiGuard® in liver surgery using 
a reproducible and clinically relevant animal model.
A novel ORC system, SurgiGuard® (Samyang 
Biopharmaceuticals Corp.), has received approval from 
the Korean FDA (product license no. 47, 30/09/2014 
KFDA). The present study was performed to evaluate the 
hemostatic effects of SurgiGuard® in liver surgery using 
a reproducible and clinically relevant animal model.
MATERIALS AND METHODS
Material
SurgiGuard® is a type of ORC. Because, this agent has 
similar chemical structure, it can be used like Surgicel®. 
SurgiGuard® is available as a woven patch, i.e., 
SurgiGuard-fabric® (Fig. 1). Like Surgicel®, SurgiGuard® 
is designed to assist in the control of capillary, venous, 
and small arterial hemorrhage when standard surgical 
techniques are ineffective or impractical.
Methods
This study was conducted in accordance with the Korea 
Food and Drug Administration notification No. 2012-61 
‘Good Laboratory Practice’ (Aug 24, 2012) and 
Organization for Economic Co-operation and Development 
Principles of Good Laboratory Practice (1997) in con-
sultation with the sponsor and was approved by our 
Institutional Animal Care and Use Committee (Approval 
No. IACU 12-KE-054).
Fifteen mini-pigs (35±5 kg) (Medikinetics mini-pig 
supplies and services) were randomly allocated into 3 
groups: SurgiGuard® (Group C [test], n=5), Surgicel® 
(Group B [reference], n=5), or none (Group A [control], 
n=5). Before surgery, all mini-pigs were weighed and 
blood samples were taken to determine the complete 
blood cell count (CBC), including white blood cell 
(WBC), red blood cell (RBC), and platelet (PLT) counts; 
C-reactive protein (CRP); and liver function tests (LFT), 
including alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST). Anesthesia was induced with zo-
letil and rompun, and the hair in the surgical region 
(upper abdomen) was removed. Endotracheal intubation 
was performed and anesthesia was maintained by iso-
flurane inhalation. The animals were monitored during the 
procedure by recording the pulse rate and oxygen 
saturation. 
The surgical region was disinfected with povidone io-
dine and alcohol, followed by the opening of the upper 
abdominal cavity for liver exposure. Similar to human liv-
er resection, the hepatoduodenal ligament was dissected, 
and the left lobe was identified for wedge resection. 
Parenchymal resection of the liver was performed using 
the Kelly clamp-crushing technique. If the number of 
bleeding blood vessels was ＞1, all bleeding blood vessels 
were closed with forceps except for one blood vessel. 
However, if the number of bleeding blood vessels was 
＜1, blood vessels were incised to generate one bleeding 
vessel. Subsequently, ORC of either Surgicel® or 
SurgiGuard® was applied to the resection margin. The re-
sected liver was weighed.
Blood loss was measured at the time of exposing the 
resection margin after the confirmation of hemostasis. 
Blood loss was measured for 5 minutes after the resection. 
If bleeding was not stopped after 5 minutes, this was re-
garded as a failure of 1st hemostasis, and blood loss was 
measured twice at every 2 minutes (i.e., 7 minutes and 
9 minutes after resection). The control group received no 
topical treatment at the resection margin after liver 
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Fig. 2. Experimental procedures: (A) After wedge resection, (B) Application of hemostatic material, (C) Blood absorption by 
sterilized gauze and (D) Measurement of blood loss.
resection. For the 1st hemostasis in the control group, ref-
erence group and test group, cotton gauze sheets were ap-
plied to the resection margin immediately after resection. 
Five minutes later, one sheet was applied if 1st hemostasis 
had not been achieved; this was repeated 2 minutes later 
if complete hemostasis had not been achieved at the 2nd 
measurement (at 7 minutes after resection). If complete 
hemostasis was not achieved after the 3rd measurement (at 
9 minutes after resection), a mechanical or thermal meth-
od was performed to stop the bleeding.
Detailed measurement of blood loss was performed as 
follows. In the control group, one sheet of a sterilized wa-
terproof surgical drape was placed below the region of re-
section, and blood was absorbed by sterilized gauze im-
mediately after the liver resection. In the reference group 
and test group, two sheets of sterilized waterproof surgical 
drapes were placed below the region of resection. 
Surgicel® and SurgiGuard® were applied and one sheet of 
surgical drapes was removed at the same time. The blood 
in the surgical field was absorbed by sterilized gauze. The 
wet gauzes were weighed, and the blood loss was calcu-
lated as the difference between the weight of the wet 
gauze and the premeasured weight of the dry gauze (Fig. 2).
After measurement of the blood loss, the surgical re-
gion was arranged to avoid adhesion with the resection 
margin of the liver. The muscle and skin were then 
sutured. The time of every procedure of the operation was 
recorded.
After surgery, the animals were permitted food and wa-
ter as normal upon recovery from anesthesia. They were 
subsequently monitored once daily. If any abnormality 
was found, the type and date of occurrence and severity 
of signs were recorded for each abnormality. All animals 
were weighed once weekly throughout the experimental 
period. One week after the operation, a blood sample was 
taken to measure the same parameters determined 
preoperatively.
The animals in each study group (control, reference, 
and test) were randomly divided into 2 subgroups for 
necropsy. Two mini-pigs were allocated to 1st necropsy 
group and the other 3 mini-pigs were allocated to 2nd nec-
ropsy group. Necropsy was performed 4 weeks after the 
operation in the 1st necropsy group and 6 weeks after sur-
gery in 2nd necropsy group. All mini-pigs were fasted be-
fore their necropsy for at least 12 hours. Before anes-
thesia, another set of blood samples was obtained from 
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Table 1. Basic porcine characteristics
Group A Group B Group C p-value
Weight (kg)
WBC (103/l)
RBC (106/l)
PLT (103/l)
CRP (mg/L)
AST (IU/L)
ALT (IU/L)
33.2
9.59
6.50
354
12
39
35
(32.2-34.7)
(8.36-11.48)
(6.25-6.81)
(321-439)
(10-15)
(32-45)
(28-41)
35.7
11.4
6.92
387
11
40
36
(35.4-36.4)
(9.59-12.47)
(6.33-7.40)
(263-509)
(10-15)
(33-47)
(27-37)
34.8
8.8
7.17
337
11
35
41
(33.7-35.3)
(8.11-10.28)
(6.45-7.39)
(280-502)
(10-12)
(30-45)
(29-56)
0.003*
0.066
0.129
1.000
0.484
0.595
0.336
Data are median (range). Group A: control group; Group B: reference group; Group C: test group. *A vs. B: p=0.032, B vs. 
C: p=0.008, C vs. A: p=0.008. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CBC, complete blood cell count;
CRP, C-reactive protein; PLT, platelets; RBC, red blood cells; WBC, white blood cells
Fig. 3. Total blood loss according to hemostatic agent. (A)
Control group, (B) Reference group and (C) Test group.
each mini-pig. The animals were deeply anesthetized with 
zoletil and rompun and euthanized by exsanguination 
from the carotid artery. The resected livers were examined 
grossly. After recording the results, the livers, including 
resection margins, were fixed in 10% neutral formalin 
solution. They were then embedded in paraffin, and mi-
crosections with a thickness of 4-5 m were made from 
the blocks. Hematoxylin & Eosin - stained slides were 
prepared, and the specimens were examined with an opti-
cal microscope.
Statistical analysis
Differences between the 3 groups were evaluated by the 
Kruskal-Wallis test. If significant differences were identi-
fied, post-hoc analysis was conducted using the 
Mann-Whitney test adding Bonferroni’s method for cor-
rection of type I error to perform pair-wise comparisons 
between groups. Changes in pre- and post-operative labo-
ratory parameters were evaluated using the Wilcoxon 
signed-rank test. The criterion for statistical significance 
was p-value＜0.05 and adjusted p value by Bonferroni’s 
method was p＜0.017. The commercial statistical pro-
gram, SPSS 20.1 software, was used for the analyses. The 
data were presented using nonparametric method, except 
when indicated otherwise.
RESULTS
Baseline porcine characteristics
The baseline characteristics of the 15 mini-pigs who 
underwent left hepatectomy are shown in Table 1. Their 
median body weight was 33.2 kg in the control group, 
35.7 kg in the reference group and 34.8 kg in the test 
group, showing significant difference (overall p=0.003, 
control vs. reference: p=0.008, reference vs. test: p=0.008, 
test vs. control: p=0.032). The preoperative CBC, CRP, 
and LFT values were not significantly different among the 
three groups.
Hemostasis during liver resection
The only significant difference in the median weight of 
the resected liver was observed between control group 
(2.13 g) and reference group (2.01 g) (p=0.024 for overall 
comparison and p=0.016 for control vs. reference). There 
were no significant differences between test group and 
control group (p=0.095) or between reference group and 
test group (p=0.151). Blood loss after the application of 
SurgiGuard® (median 35.52 g) and Surgicel® (median 
32.52 g) was significantly lower than blood loss in the 
control group (median 57.18 g) (p=0.008 for the overall 
comparison, p=0.008 for control vs. reference, and 
p=0.008 for test vs. control). However, blood loss was not 
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Table 3. Changes between preoperative and postoperative laboratory parameters
Parameter Group Pre-resection Post-resection p-value Necropsy p-value
WBC (103/l)
 
 
RBC (106/l)
 
 
PLT (103/l)
 
 
CRP (mg/L)
 
 
AST (IU/L)
 
 
ALT (IU/L)
 
 
A
B
C
A
B
C
A
B
C
A
B
C
A
B
C
A
B
C
9.59 (8.36-11.48)
11.4 (9.59-12.47)
8.80 (8.11-10.28)
6.50 (6.17-6.92)
6.92 (6.33-7.40)
7.17 (6.45-7.39)
354 (321-439)
387 (263-509)
337 (280-502)
 12 (10-15)
 11 (10-15)
 11 (10-12)
 39 (32-45)
 40 (33-47)
 35 (30-45)
 35 (28-41)
 36 (27-37)
 41 (29-56)
12.05 (8.47-15.58)
10.54 (8.01-13.71)
10.74 (8.17-11.13)
 6.60 (6.09-6.87)
 7.34 (6.34-7.65)
 7.01 (6.66-7.69)
 277 (228-432)
 297 (265-352)
 311 (289-420)
  11 (10-13)
  12 (11-15)
  11 (10-14)
 181 (142-211)
 122 (108-145)
 186 (129-215)
 176 (131-457)
 110 (93-143)
 141 (109-181)
0.225
0.345
0.500
0.786
0.043
0.893
0.043
0.183
0.686
0.465
0.059
0.705
0.043
0.043
0.043
0.180
0.043
0.043
 8.52 (7.47-18.14)
11.57 (8.89-13.32)
11.09 (7.11-15.82)
 6.18 (5.98-6.89)
 6.13 (5.3-8.1)
 6.80 (5.84-7.16)
 321 (285-458)
 327 (143-352)
 296 (184-449)
  12 (10-13)
  11 (10-13)
  10 (10-14)
  38 (35-39)
  39 (30-43)
  29 (22-48)
  35 (31-38)
  31 (21-35)
  36 (21-60)
0.893
0.686
0.138
0.063
0.138
0.063
0.138
0.138
0.080
0.450
0.854
0.655
0.345
0.345
0.345
0.893
0.279
0.686
Data are median (range). Group A: control group; Group B: reference group; Group C: test group. ALT, alanine aminotransferase;
AST, aspartate aminotransferase; CBC, complete blood cell count; CRP, C-reactive protein; PLT, platelets; pre, preoperative; 
post, postoperative; RBC, red blood cells; WBC, white blood cells
Table 2. Resection characteristics: weight of resected liver and blood loss
Group A Group B Group C p-value
Liver weight (g)
Blood loss (g)
  0-5 min
  5-7 min
  7-9 min
Total blood loss (g)
2.13
 
44.15
6.40
4.14
57.18
(2.02-2.20)
 
(43.12-49.06)
(5.30-9.64)
(3.60-5.98)
(52.02-59.54)
2.01
 
25.69
4.20
3.00
35.52
(1.99-2.12)
 
(21.58-29.38)
(1.70-7.41)
(0.00-3.20)
(25.70-38.71)
2.04
 
24.50
6.01
2.01
32.52
(2.01-2.13)
 
(23.50-26.50)
(3.59-8.16)
(0.00-3.26)
(27.66-35.10)
0.024*
 
0.009†
0.196†
0.006‡
0.008#
Data are median (range). Group A: control group; Group B: reference group; Group C: test group. *A vs. B: p=0.095, B vs.
C: p=0.151, C vs. A: p=0.016. †A vs. B: p=0.008, B vs. C: p=0.690, C vs. A: p=0.008. ‡A vs. B: p=0.008, B vs. C: p=0.222,
C vs. A: p=0.008. #A vs. B: p=0.008, B vs. C: p=0.548, C vs. A: p=0.008
significantly different between the test group and refer-
ence group (p=0.548) (Fig. 3). During subgroup analysis 
according to time periods, blood loss at 0-5 minutes and 
7-9 minutes was significantly different between groups at 
both 0-5 minutes and 7-9 minutes. Median blood loss at 
0-5 minutes was as follows: control group 44.15 g; refer-
ence group 25.69 g; and test group 24.50 g (p=0.009). At 
7-9 minutes, the median blood loss was as follows: con-
trol group 4.14 g; reference group 3.00 g; and test group 
2.01 g (p=0.006) (Table 2).
Changes in laboratory parameters after liver 
resection
Comparing preoperative laboratory parameters, includ-
ing CBC and CRP, to postoperative laboratory parameters 
on postoperative day #7, there were no significant differ-
ences between the groups. By contrast, changes in LFT 
exhibited significant differences. The median AST level 
increased significantly from preoperatively to post-
operatively in all groups: control group 39 IU/L vs. 181 
IU/L (p=0.043); reference group 40 IU/L vs. 122 IU/L 
(p=0.043); and test group 35 IU/L vs. 186 IU/L (p=0.043). 
The median ALT level increased significantly from pre-
operatively to postoperatively in only reference and test 
group: control group 35 IU/L vs. 176 IU/L (p=0.180; ref-
erence group 36 IU/L vs. 110 IU/L (p=0.043); and test 
group: 41 IU/L vs. 141 IU/L (p=0.043). However, the 
LFT values returned to the normal range by the necropsy 
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Table 4. The results of the mini-pig necropsies
Time Findings Group A Group B Group C
POD #28
 
 
POD #42
 
 
Total
Enveloped in opaque membrane at resection margin
Foreign material
Adhesion to other organs
Enveloped in opaque membrane at resection margin
Foreign material
Adhesion to other organs
 
2 (100)
0 (0)
0 (0)
3 (100)
0 (0)
0 (0)
5
2 (100)
2 (100)
0 (0)
3 (100)
0 (0)
0 (0)
5
2 (100)
2 (100)
0 (0)
3 (100)
0 (0)
0 (0)
5
Data are number (%). Group A: control group; Group B: reference group; Group C: test group. POD, postoperative day
Table 5. Histopathological findings of the resected livers
Time Findings Group A Group B Group C p-value
POD #28
 
 
POD #42
 
 
Total
Congestion/hemorrhage
Chronic inflammation
Vacuolar degeneration of hepatocytes
Congestion/hemorrhage
Chronic inflammation
Vacuolar degeneration of hepatocytes
 
1 (50)
1 (50)
0 (0)
2 (66.7)
2 (66.7)
0 (0)
5
2 (100)
1 (50)
2 (100)
3 (100)
2 (66.7)
0 (0)
5
2 (100)
1 (50)
1 (50)
3 (100)
2 (66.7)
0 (0)
5
1.000
1.000
0.600
1.000
1.000
1.000
 
Data are number (%). Group A: control group; Group B: reference group; Group C: test group. POD, postoperative day
date (Table 3).
Necropsy and histopathological findings
During necropsy, no hematomas, granulomas, or adhe-
sions were observed in any group. In reference and test 
group, foreign body material noted in the postoperative 
day #28 pigs were not observed in the postoperative day 
#42 mini-pigs (Table 4). Histopathological analysis re-
vealed no changes suggesting toxicity related to the hemo-
static agents in either reference or test group (Table 5).
DISCUSSION
Several hemostatic agents can overcome the unsat-
isfactory hemostatic effects of woven cotton gauze. 
Because the ideal hemostatic material should have ample 
hemostatic action, minimal tissue reactivity, low cost, in 
vivo biodegradability, and lack of antigenicity, analyses 
of the clinical benefits and risks of such materials should 
be performed by considering these qualities as standards.8
Since ORC was first described in 1943, numerous stud-
ies have shown the hemostatic effects of ORC, including 
when used for hepatectomy.9-11 In addition to its applica-
tion in laparotomy or laparoscopic surgery, ORC is now 
also used for hemostasis during endoscopic procedures.12 
The results of the current study were similar to those pre-
viously reported. Although the median weights of the re-
sected liver differed between groups, statistically sig-
nificant differences were only demonstrated between the 
control and reference groups. Therefore, this factor did 
not influence the blood loss comparisons between the test 
and reference groups. Moreover, because the weight of 
the resected liver does not always represent the extent of 
the resected surface margin, the correlation between the 
resected liver weight and the amount of blood loss may 
be of minor importance. The time required to achieve he-
mostasis is an important determinant of the amount of 
blood loss. In our study, two cases of complete hemostasis 
within 5-7 minutes occurred in the test as well as the ref-
erence group, and there were significant differences in 
blood loss between the control group and treated groups 
at 7-9 minutes. These data suggested that the use of the 
ORC agents promoted time-saving during liver resection.
Because the presence of a foreign body increases the 
susceptibility to infection, most local hemostatic agents 
may increase infection and should not be used in an in-
fected wound.13,14 However, ORC is resistant to infection 
because its acidic pH is fatal to bacteria.15 In the current 
study, laboratory parameters that suggest the presence of 
an infection, such as WBC and CRP, showed no sig-
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nificant preoperative to postoperative change. In addition, 
abscess or other infectious changes were absent at 
necropsy. This result, therefore, suggests that SurgiGuard® 
was not toxic to the host cells.
Healing quality is also important after the implantation 
of any medical material or device, and minimum in-
flammation without a strong foreign body reaction or in-
hibition of the healing process is desirable. The anti-adhe-
sive effectiveness of ORC is previously reported.16,17 To 
improve upon this characteristic, a novel agent, 
Interceed®, was developed and used for various types of 
surgery, especially gynecologic operations.18,19 Although 
microscopic examination revealed chronic inflammatory 
changes at the liver surface in the current study, no adhe-
sions were observed around the liver on gross examination 
during necropsy.
ORC reportedly dissolves promptly in various sites 
without toxicity, with complete dissolution by 6 weeks.6,20 
Migrated ORC is occasionally mistaken for abscess for-
mation or leads to severe complications; hence, complete 
dissolution without migration is important.21,22 In our cur-
rent study, foreign body materials were found attached to 
the liver at 4 weeks, but none were observed during the 
6-week necropsy examinations; in addition, there was no 
significant difference in LFT at the time of the necropsy 
examinations. Although changes in LFT exhibited sig-
nificant differences on postoperative day #7, the changes 
were possibly due to transient effects of liver resection 
and not from ORC toxicity. This result suggested that 
SurgiGuard® has a suitable capacity for dissolving in a 
reasonable time without toxicity and for adhering only to 
surfaces to which it is applied, but not to other organs.
This study has the major limitation of the small size 
of the experimental groups, which potentially influenced 
the evaluation of statistically significant outcomes. The 
difficulty of creating equivalent conditions is another limi-
tation of this study. Although there were no significant 
differences in PLT counts preoperatively between groups, 
and the resected liver weights were relatively similar be-
tween groups, this does not necessarily guarantee that 
each mini-pig had similar hemostatic status or resected 
liver margin area. Moreover, compared to other organs 
such as the spleen and kidney, the liver has variable spon-
taneous clotting times and rates of hemorrhage, which 
leads to difficulties in obtaining precise measurement 
values.8 Nevertheless, SurgiGuard® exhibited significant 
hemostatic effects compared to the control group, which 
were equivalent to the effects exhibited by the reference 
agent. Furthermore, no toxic changes and adhesions to 
other organs were observed at the resection margin during 
the entire experimental period in mini-pigs who were 
treated with SurgiGuard®.
In conclusion, the current study suggested that the nov-
el ORC, SurgiGuard®, could be as effective as Surgicel® 
in achieving hemostasis after porcine liver resection. To 
overcome the limitations of this study, future studies 
should be performed to provide more data regarding sys-
temic environment such as similar hemostatic condition 
and obtaining similar resection margin.
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